Vice President of Chemistry
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses.
Successful drug discovery chemistry team leader with an over 20 year history in guiding lead discovery programs to drug candidate phase. Experience includes the discovery of lead candidates in the Alzheimer's Disease, Cancer, Inflammation, Dermatology, and Bone Growth therapeutic areas pursuing such targets as GPCRs, kinases, nuclear hormone receptors, and enzymes while executing compound structure-activity/property relationship programs driven by structure biology, molecular modeling, pharmacokinetic optimization, and intuition. Effective leader of cross-discipline and cross-organization collaborations that have generated leads and intellectual property advancing the knowledge and treatment of human diseases and conditions. Inventor on numerous issued/granted patents and fulfilled role as project (Big Pharma) and company (Cayman) intellectual property liaison and manager. Understanding mentor of colleagues and students.